Population
cancer, tumor
MAY, TUMOR, CANCER
Between October 2015 and May 2017, 27 cancer centers participated in the CHEOPS trial. The participating centers was diverse, with private, public and dedicated cancer centers. Overall, 121 patients were included and randomized: 61 patients received oral vinorelbine (Arm A) and 60 patients a combination of oral vinorelbine and aromatase inhibitor (Arm B) (Fig. Flowchart. AI: aromatase inhibitor. *Other reasons for premature stop were decisions from investigator, sponsor, steering committee or IDMCPatient, tumor and treatment characteristicsTable does not include missing data; no significant difference found with Fisher's test and Chi